Medidata Solutions Inc (NASDAQ:MDSO) Director Carlos Dominguez sold 9,066 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $66.85, for a total transaction of $606,062.10. Following the transaction, the director now directly owns 66,020 shares of the company’s stock, valued at $4,413,437. The sale was disclosed in a document filed with the SEC, which is available through this link.
Medidata Solutions Inc (NASDAQ MDSO) opened at $64.58 on Thursday. The firm has a market cap of $3,799.38, a price-to-earnings ratio of 78.30, a price-to-earnings-growth ratio of 4.05 and a beta of 1.69. Medidata Solutions Inc has a 1-year low of $47.77 and a 1-year high of $85.92. The company has a quick ratio of 3.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.61.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The company had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. Medidata Solutions’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the business earned $0.28 EPS. equities research analysts expect that Medidata Solutions Inc will post 0.77 earnings per share for the current year.
A number of brokerages have recently weighed in on MDSO. Royal Bank Of Canada began coverage on shares of Medidata Solutions in a research note on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 price objective for the company. SunTrust Banks reaffirmed a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a research note on Friday, October 27th. Wells Fargo & Company lowered their target price on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research note on Friday, October 27th. Dougherty & Co assumed coverage on shares of Medidata Solutions in a research note on Thursday, November 2nd. They issued a “neutral” rating for the company. Finally, Zacks Investment Research raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Friday, November 10th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $85.08.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
What are top analysts saying about Medidata Solutions Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Medidata Solutions Inc and related companies.